ABSTRACT
1) Neurophysiopatology and 2) Department of Pharmaceutical and Biomedical Sciences, University of Salerno, Italy.
At present, it is contradictory to determine if the combination of certain prothrombotic polymorphisms and migraine and also the risk to develop ischaemic vascular disease. Recently, the common Val34Leu polymorphism of the A-chain factor XIII gene, associated with variations in factor XIII activity, has been suggested to play a significant role in the development of arterial and venous thrombotic disorders.
Our study analysed the incidence of genetic polymorphism Factor XIII (V34L) in a sample of migraineurs and a control group of the patients with ischemic cardiopaty.
In this study 100 consecutive patients aged 18-64 years (mean age 33.7 years), suffering from migraine [1] (78 migraine without aura, 22 migraine with aura, ICHD-II criteria ) and 90 patients aged 36-74 years (mean age 46.5 years), with ischemic cardiopathy [2] were studied with Polymerase Chain Reaction (PCR) for genetic polymorphism Factor XIII (V34L).
Factor XIII (V34L): 62 subjects (62%) [1] and 40 (44.4%) [2] were heterozygous; 6 subjects (6%) [1] and 5 (5.5%) [2] were mutated.
These data evidenced that the incidence the factor XIII Leu 34 allele in two population studied not evidenced meaningful differences. Therefore a role in the pathogenesis of such disturbances is hypothetical and deserves ulterior deepenings in more important casuistries.